Kornimate/medical-research-clean huggingface dataset:
effects of recombinant human thrombopoietin on platelet levels in icu patients

Conditions: Pneumonia; Thrombocytopenia

Summary: the incidence of thrombocytopenia in icu patients with severe illness ranged from 8.3% to 67.6%, and ranged from 14% to 44% during icu treatment.severe patients with thrombocytopenia also have significantly increased bleeding events and blood transfusions, and even a significantly increased risk of death.this study examines whether elevated platelets benefit patients with pneumonia


Eligibility criteria:
inclusion criteria: * clinical diagnosis of pneumonia (community acquired pneumonia, hospital acquired pneumonia or ventilator associated pneumonia); * voluntarily signed informed consent; * ≥18 years old; * platelet count ≤75×109/l exclusion criteria: * a history of hematopoietic stem cell transplantation or solid organ transplantation such as liver, kidney or lung; * hematological malignancy; * immune thrombocytopenia, such as sle, itp, ttp, etc. * the length of stay in icu is less than 24h; * pregnant or lactation patients;
first-in man (fim) study mr-linac

Conditions: Bone Metastases

Summary: investigational device is the magnetic resonance imager linear accelerator. five (5) patients with bone metastases will be treated with palliative intention in this study. the goal is to confirm the pre-clinically demonstrated technical accuracy and safety of the newly developed mr-linac in the clinical setting.

this is a single center prospective proof of concept study including accuracy and safety aspects according to r-ideal stage 1 criteria. five (5) patients with bone metastases will be treated with palliative intention in this study. treatment will consist of a single fraction. the mr linear accelerator (mrl) integrates a radiotherapy accelerator and a diagnostic quality 1.5t mri, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. this enables on-line treatment optimization for precise radiation delivery. better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.

Eligibility criteria:
inclusion criteria: in order to be eligible to participate in this study, a patient must meet all of the following criteria: * painful bone metastases in the lumbar spine * radiographic evidence of bone metastases * histologic proof of malignancy (primary carcinoma) * karnofsky performance score ≥ 50 * age ≥ 18 years * able to provide written informed consent exclusion criteria: a potential subject who meets any of the following criteria will be excluded from participation in this study: * prior radiation therapy within the region planned to be irradiated * contraindication for mri according to screening protocol radiology department umcu (e.g. cardiac pacemakers, and defibrillators, artificial heart valves or cochlear implants, https://richtlijn.mijnumc.nl/beeld/mri/paginas/mri-veiligheid-contra-indicaties.aspx * claustrophobia * standard systemic anti-cancer therapy or radionuclide therapy within 48 hours before or after treatment. * any other type of not standard systemic anti-cancer treatment, except for endocrine treatment. * unstable spine requiring surgical stabilization * neurological deficit due to bone metastasis
the effects of virtual reality on upper extremity function in hemiplegic cerebral palsy

Conditions: Cerebral Palsy

Summary: the investigators have planned a research on the effects of virtual reality therapy and home exercise program on hand functions in children with hemiplegic cerebral palsy in istanbul university istanbul faculty of medicine in the department of physical medicine and rehabilitation. the eligible patients will be randomized into two groups. the patients in intervention group will participate in a computer based virtual reality exercise program for a period of 8 weeks supervised by the investigators. in addition, these patients will receive a home exercise program. the patients in the control group will receive only a home exercise program for 8 weeks. all patients will be evaluated before treatment, immediately after treatment, and 3 months after the end of the treatment.

the current study is a prospective, randomized controlled interventional trial, which will conduct in the istanbul university istanbul faculty of medicine in 2016. the study was approved by the ethics committee in conformity with the declaration of helsinki. prior to data collection, all participants will provide informed consent. by the order of application to the outpatient clinics, the eligible participants will randomly allocated to two groups using the computer-generated random numbers: intervention group (n=17) and control group (n=17). information on demographic characteristics (age, gender, body mass index, educational level), pre-natal history, parent educational level and past medical history will obtain at baseline assessment. after baseline assessment, the patients in intervention group will participate in a computer based virtual reality exercise program with handtutor equipment. the supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. in addition, these patients will receive a home exercise program. the patients in the control group will receive only a home exercise program for 8 weeks. the home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand. all patients will be evaluated before treatment, immediately after treatment, and 3 months after the end of the treatment.

Eligibility criteria:
inclusion criteria: * children with hemiplegic cerebral palsy diagnosed by the specialist * active wrist extension ≥ 20 ° * gross motor function classification system score: 1-2 * manual ability classification system score: 1-3 * the ability to follow simple commands and participate in the task exclusion criteria: * contracture in upper limb * absence of vision and hearing problems * uncontrolled seizure * lack of movement in the hemiplegic upper limb * history of orthopedic surgery (tendon transfer / tendon lengthening) to the affected upper extremity * any treatment for upper limb in the last 6 months including btx-a or orthopedic interventions

Keywords: virtual reality hemiplegic cerebral palsy upper extremity hand function
survival of endocrowns made from different ceramics

Conditions: Pulp Disease, Dental; Dental Caries; Dental Leakage

Summary: restoration of endodontically treated teeth requires a means to protect the cusps from the wedging forces of occlusion. when there is extensive loss of tooth structure, cuspal coverage is warranted. usually this is in the form of indirect restoration. traditionally, full coverage crowns have been used which would require further removal of sound tooth structure. recently, adhesive alternatives have been introduced which allow for conservation of tooth structure. different materials can be used for this purpose. the evidence on the long-term survival of these materials is scarce. this study aims to investigate the short and medium-long term survival rate of these prostheses.


Eligibility criteria:
inclusion criteria: * root canal treated molars with significant loss of tooth structure * supra-gingival margins * teeth scheduled for cuspal-covering indirect restorations exclusion criteria: * teeth with extensive cracks or fractures * teeth with deep subgingival margins * non-functional teeth (no opposing dentition) * teeth with advanced periodontitis
visual prognosis in non-penetrating corneal blast injuries

Conditions: Corneal Foreign Body Following Blast Injury

Summary: the purpose of this study is to assess visual quality of patients with non-penetrating, non-metallic, stable corneal foreign bodies. visual quality will be assessed by examining visual acuity, wavefront analysis and contrast sensitivity. drawings, photographs, and confocal microscopy will be used to document clinical examination of the cornea at baseline and on follow-up examinations.


Eligibility criteria:
inclusion criteria: * informed consent * access to medical care at walter reed army medical center * age 18 years or older * corneal foreign bodies from blast injuries * available for evaluation at walter reed exclusion criteria: * residual, recurrent or active ocular disease in the designated eye as determined by exam and history. * penetrating ocular trauma or injury to the posterior segment * prior history of ocular surgery * any physical or mental impairment that would preclude participation in any of the examinations. * any ocular abnormality other than corneal foreign bodies that have any impact on vision (i.e. other abnormalities from trauma such as retinal detachment, corneal laceration, traumatic cataract, or abnormalities unrelated to trauma such as herpes.
study on the biological prediction models of radiation pneumonitis

Conditions: Radiation Pneumonitis

Summary: radiation pneumonitis is the most common complication and the major dose-limiting toxicity associated with radiotherapy, which can cause poor quality of life or life-threatening symptoms and might hinder the tumor-controlling effects of radiotherapy. consequently, establishing reliable predictors for the occurrence of rp is of great significance such that the therapeutic effects of rt can be maximized while minimizing its adverse effects. the aim of this study is to figure out the biological prediction models of radiation pneumonitis.

1. establish a clinical data base for the lung cancer patients treated with radiotherapy in tongji hospital. data including age, gender, smoking state, kps, pulmonary function, disease history, histology, stage, surgery, chemotherapy, dosimetric parameters of radiotherapy were collected. peripheral blood was collected from all patients enrolled. all patients enrolled in this study are examined during and one month after radiotherapy. then, the patients are followed every three months for the first year and every six months thereafter. at each follow-up visits, all patients are asked to undergo a chest x-ray or ct and clinical information, including symptoms, is collected. rp is graded by two radiation oncologists according to the common terminology criteria for adverse events 4.0. 2. select candidate genes and pathways which may be associated with radiation pneumonitis and identify their tagsnps by haploview. 3. use kaplan-meier and cox model to analyze the association of all the factors collected with radiation pneumonitis. 4. establish a biological prediction models for radiation pneumonitis based on the statistics analysis

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of lung cancer by histology 2. radiation dose at least 45 gy 3. kps\>60 4. life expectancy of at least 6 months 5. voluntarily signed the informed consent exclusion criteria: 1. previous thoracic irradiation 2. severe cardiopulmonary diseases

Keywords: radiation pneumonitis lung cancer prediction models genetic variants
design and development of a novel food supplement for osteoporosis based on gut microbiome mechanisms

Conditions: Osteopenia; Postmenopausal Osteopenia

Summary: it is well proven that the intestinal microbe regulates bone metabolism by the absorption of calcium and other metallic trace elements. studies also show that regulation of the intestine and its microbe can affect bone density and resistance to a variety of animal models and humans. at the same time, interest in polyphenol-intestinal microbial interactions and in particular flavonoids and catechins has increased. indeed, it has been observed that they are transformed via the microbe into bioactive compounds, and polyphenols themselves can modify the synthesis of the intestinal microbe. osteome aspires to design and develop a novel dietary supplement for osteoporosis, activating the intestinal microbiome. at the same time companion biomarkers will be studied related to the efficacy and tolerability of the new supplement. the selection of flavonoids will take place through in vitro and in silico studies focusing on their interaction with pathways that regulate the activity of osteoclasts and osteoblasts. the efficacy and tolerability of the dietary supplement will be evaluated through a randomized clinical intervention.


Eligibility criteria:
inclusion criteria: * postmenopausal women * t-score in the osteopenic range (-1.0 \> t-score \> -2.5) at either the lumbar spine (ls) or femur as measured by dual energy x-ray absorptiometry (dxa) exclusion criteria: * t-score in the osteoporotic range (t-score \< -2.5) at any site * patients receiving supplements of calcium and/or vitamin d at that time or during the last 6 months * patients receiving medications known to positively or negatively affect bone turnover or bmd at that time or during the last 3 years (e.g. antiresorptive agents, oestrogens, systemic corticosteroids), or * secondary cause of osteoporosis (e.g. alcohol abuse, thyrotoxicosis etc) * patients who did not attend to their follow-up appointment and consequently had only the baseline measurements

Keywords: dietary supplement for osteopenia calcium and vitamin d supplement calcium, vitamin d and prebiotics supplement calcium, vitamin d, prebiotics and flavonoids supplement bone turnover markers bone mineral density volumetric bone mineral density bone geometry postmenopausal osteopenia gut microbiota analysis
ati evidence-based guide investigating medical and preventative services

Conditions: Sport Medicine

Summary: the investigators goal is to provide a mechanism that allows for a better understanding of athlete management from injury prevention through maintenance of health or development of injury and rehabilitation. the goal is to describe best practice for prevention and treatment to maximize return to health, sport, and patient reported outcomes following time. this includes collection of pre-existing risk factors, prevention program participation, treatment initiatives, functional outcomes measured by standardized and validated tools from the published literature. it incorporates comorbidities and patient demographic characteristics. all of these components come together to form a remarkably comprehensive picture of athlete health, influencing factors, and their associated outcomes.

the investigators goal is to provide a mechanism that allows for a better understanding of athlete management from injury prevention through maintenance of health or development of injury and rehabilitation. the goal is to describe best practice for prevention and treatment to maximize return to health, sport, and patient reported outcomes following time. this includes collection of pre-existing risk factors, prevention program participation, treatment initiatives, functional outcomes measured by standardized and validated tools from the published literature. it incorporates comorbidities and patient demographic characteristics. all of these components come together to form a remarkably comprehensive picture of athlete health, influencing factors, and their associated outcomes. data are collected via the athletic training electronic medical record system emr and integrated with data from the investigators proprietary emr system and are genuine to the community through clinical process. the data are collected in real-time with athletes and patients and the scores are immediately provided to the providing athletic trainer and therapist as well as archived for later registry and scientific use. subsequent reporting can be adjusted to any variable collected which yields robust insights as to athlete health. however, no phi information will be available.

Eligibility criteria:
inclusion criteria: active in an organized sports team, exclusion criteria: none

Keywords: concussions fractures instability sprains strains
early non invasive ventilation in immuno-compromized patients with acute respiratory failure.

Conditions: Adult; Acute Respiratory Failure Admitted in ICU; Immuno Compromized

Summary: assess the superiority of early non invasive ventilation in comparison to oxygen therapy only, for immuno-compromized patients with acute respiratory failure


Eligibility criteria:
inclusion criteria: * age over 18 years old * icu admission * acute respiratory failure defined by (pao2\ 30/min or dyspnea at rest) or respiratory distress. since less than 72 hours. * immuno compromized patient defined by solid tumor (treated since less than 5 years) or haematological malignancy (treated since less than 5 years) or solid organ transplantation or stem cell transplantation or immunosuppressive treatment (steroid \> 1mg/kg/d or \>1 month or other immunosuppressive treatment \>1 month) exclusion criteria: * hypercapnia \>50 mmhg or increased of hypercapnia \>10 mmhg under oxygen treatment * need of immediate mechanical ventilation * obvious cardiogenic oedema * vasopressor use \>0.03 µg/kg/min * glasgow score \<13 * end of life decision * acute myocardial infarction * patient refusal * pregnancy * no national health insurance
high flow oxygen therapy vs standard care in infants with viral bronchiolitis

Conditions: Bronchiolitis, Viral

Summary: a randomized control trial of 130 infants admitted to the paediatric high care admission ward will be enrolled, and randomized to either "high flow humidified oxygen" or "standard therapy".

a randomized control trial of 130 infants admitted to the paediatric high care admission ward will be enrolled. infants between 1 month and 2 years of age who fulfill criteria for enrollment shall be considered eligible. informed consent from parents or legal guardians shall be obtained. infants shall be randomized to either "standard therapy" or "high flow humidified oxygen". measurements of heart rate, respiratory rate, work of breathing (tal score and wcas), oxygen saturation and oxygen requirements shall be recorded.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of viral bronchiolitis * not requiring intubation and ventilation * admitted to high care unit * with moderate/severe respiratory distress (tal score \>6) * saturations \<92% in room air exclusion criteria: * congenital cardiac disease * presence of multiorgan failure/multisystemic disease * previously ventilated * craniofacial abnormalities * nasal pathology * decreased level of consciousness * ex-prem \<34 weeks * possible impending respiratory failure
care china-diabetes

Conditions: Cardiovascular Disease; Diabetes

Summary: this multicenter, prospective, observational registry will assess efficacy and safety outcomes associated with percutaneous coronary intervention (pci) with implantation of the cypher select™+ sirolimus-eluting coronary stents in chinese diabetic patients with coronary artery disease in routine clinical practice.

the study objective is to assess the incidences of major adverse cardiovascular events (mace; defined as a composite of clinically driven target-lesion revascularization, cardiac death, any myocardial infarction, and stent thrombosis) at 12-month follow-up, and of stent thrombosis at 1-day, and 1- and 12-month follow-up. pre-specified analyses will be performed among patient subpopulations according to level of glycemic control (hba1c level \ 6.5%); reference vessel diameter by quantitative coronary angiography (\ 2.5 mm); and stented length (8-18 mm; 23-33 mm; and \>33 mm). quantitative coronary angiographic (qca) analysis will be performed at the core lab of the china cardiovascular research foundation for all pre- and post-index procedure angiograms and during the 12-month follow-up period for the pre- and post-reintervention procedures in those cases of clinically-driven pci revascularization. also, multivariable analyses will be conducted to investigate potential predictors of 12-month mace rate in routine clinical practice. the registry will be conducted at about 45 centers in china, where the cypher select™+ sirolimus-eluting coronary stent is commercially available. data will be collected on 2,500 diabetic patients treated with the cypher select™ + sirolimus-eluting coronary stent only. primary outcome: mace (clinically driven tlr, cardiac death, mi, st) at 12 months secondary outcome: arc (probable + definite) st at 1-day, and 1 and 12 months

Eligibility criteria:
inclusion criteria: * patients between the ages of 18 and 80 (inclusive) receiving cypher select™+ sirolimus-eluting coronary stent according to standard clinical practice when financially feasible * the patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethics committee of the respective clinical site. * patient has diagnosis of diabetes or is diagnosed with it before or during the index procedure hospitalization based on disease diagnosis criteria exclusion criteria: * any contraindication to any of the following medications: aspirin, heparin, thienopyridines (clopidogrel/ticlopidine), stainless steel, contrast agents, or sirolimus * an elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment * cardiogenic shock * terminal illness with life expectancy \<1 year * st-segment elevation myocardial infarction within 7 days prior to the index procedure * any patient who received coronary stent(s) within 1 year

Keywords: cardiovascular disease diabetes
a study to compare a new drug for type 2 diabetes to placebo and to a treatment already available for type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: the main purpose of this study is to compare the safety and effectiveness of the study drug known as ly2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus. all drugs will be given by an injection under the skin. participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. participants' involvement in the study is expected to last about 30 weeks.

the study will include a 12 week blinded treatment period, where neither the participant nor the investigator will know to which treatment each individual is assigned. thereafter follows a 12 week period where participants and the investigator will know which treatment they are assigned to. participants' on ly2944876 and on exenatide extended-release continue treatment in this period, those who received placebo will be followed without treatment.

Eligibility criteria:
inclusion criteria: * men or women with diabetes mellitus type 2 * have screening hba1c ≥7.0% and ≤10.5% either on diet and exercise alone or on a stable dose of metformin (≥1000 mg/day) for 3 months prior to screening * have body mass index (bmi) ≥23 and ≤45 kilograms per meter squared at screening exclusion criteria: * women of child bearing potential * participants who have used thiazolidinediones within 3 months prior to screening, or any other drugs for treatment of hyperglycemia (except metformin) within the prior 2 months * participants who have used insulin for diabetic control for more than 6 consecutive days within the prior year * participants with impaired renal function (serum creatinine \>124 micromole per liter (µmol/l) \[1.4 milligrams per deciliter (mg/dl)\] in women, \>133 µmol/l \[1.5 mg/dl\] in men)

Keywords: weight loss